Arbutus Biopharma (ABUS) CEO awarded 28,000 RSUs and 71,700 options

Rhea-AI Filing Summary

Arbutus Biopharma Corp

The RSUs vest in three equal annual installments beginning one year from the grant date, contingent on continued service, and shares will be automatically sold at vesting to cover tax withholding. She also received a stock option for 71,700 common shares at an exercise price equal to the Nasdaq closing price of $4.39 on the grant date.

This option vests over four years, with 1/48th of the shares vesting in substantially equal monthly installments starting one month after the grant date, subject to her continued service. After these grants, she directly holds 28,000 common shares and options for 71,700 shares.

02/02/2026 - 08:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Androski Lindsay

(Last) (First) (Middle)

C/O ARBUTUS BIOPHARMA CORPORATION

701 VETERANS CIRCLE

(Street)

WARMINSTER PA 18974

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arbutus Biopharma Corp [ ABUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/02/2026		A		28,000(1)	A	$0	28,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.39(2)	02/02/2026		A		71,700		(3)	02/02/2036	Common Shares	71,700	$0	71,700	D

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.

2. Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

3. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.

Remarks:

	/s/ Tuan Nguyen as attorney-in-fact for Lindsay Androski	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ABUS President and CEO Lindsay Androski report?

Lindsay Androski reported receiving equity awards from Arbutus Biopharma. She was granted 28,000 restricted stock units and a stock option for 71,700 common shares on 02/02/2026, both subject to multi-year vesting tied to her continued service with the company.

How many Arbutus Biopharma (ABUS) RSUs were granted to the CEO?

The CEO received 28,000 restricted stock units. Each RSU represents a contingent right to receive one common share, vesting in three equal annual installments starting one year after the grant date, provided she continues to serve the company on each vesting date.

What stock options did the Arbutus Biopharma (ABUS) CEO receive?

She received a stock option to buy 71,700 common shares at an exercise price equal to the Nasdaq closing price of $4.39 on the grant date. The option vests over four years in substantially equal monthly installments, starting one month after the grant date.

What are the vesting terms for the ABUS CEO’s RSU grant?

The 28,000 RSUs vest in three equal annual installments beginning one year from the grant date. Vesting requires the CEO’s continuous service at each vesting date, and at each vesting, shares will automatically be sold to satisfy tax withholding obligations.

How do the ABUS CEO’s stock options vest over time?

The 71,700-share stock option vests over four years. One forty-eighth of the shares vest in substantially equal monthly installments starting one month after the grant date, subject to the CEO remaining in continuous service through each monthly vesting date.

How many ABUS shares and options does the CEO hold after this Form 4?

Following the reported grants, the CEO directly holds 28,000 common shares and a stock option covering 71,700 common shares. These holdings reflect only the awards disclosed in this Form 4 and are subject to the detailed vesting schedules attached to the grants.